M. Maltoni et al., High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: A systematic review of randomised clinical trials, ANN ONCOL, 12(3), 2001, pp. 289-300
Background: The aim of the present study was to summarise evidence from sci
entific studies on cancer anorexia-cachexia syndrome in order to assess and
highlight the efficacy of high-dose progestins (megestrol acetate and medr
oxyprogesterone acetate) compared with placebo in patients with hormone-ind
ependent tumors.
Materials and methods: A systematic review of published randomised clinical
trials was carried out by an extensive electronic and hand search through
databases, relevant journals and books, congress proceedings, reference lis
ts, without any language or year of publication restriction. The research w
as conducted by two independent operators who collected the data in a form
specifically designed for this review. Among the several possible outcomes,
appetite and body weight were chosen.
Results: Fifteen randomised clinical trials (more than 2000 patients) were
retrieved for the review. There was a statistically significant advantage f
or high-dose progestins as regards improved appetite: pooled odds ratio (OR
) = 4.23, 95% confidence interval (CI): 2.53-7.04. Although the effect of h
igh-dose progestins on body weight was less impressive, statistical signifi
cance was also reached for this outcome: pooled OR = 2.66, 95% CI: 1.80-3.9
2.
Treatment morbidity was very low, due to the brief period of the treatment
in most of the studies.
Conclusions: The effects of high-dose progestins on appetite and body weigh
t were clearly demonstrated. However, further studies are undoubtedly warra
nted to investigate other aspects of progestin activity, especially as rega
rds dosage, duration and timing with best therapeutic index.